Frost & Sullivan, a globally recognized growth consulting firm, recently unveiled the "China RADIOPharma Industry Current State and Future Development Blueprint." This detailed report offers an in-depth analysis of the Chinese nuclear medicine industry's infrastructure and growth dynamics. It highlights technological advancements, pipeline development, supportive governmental policies, market expansion, and investor interest to illustrate the sector's technological evolution and pathways. Among the spotlighted entities, RADIOPharma emerges as a notable example within the Blueprint. This innovative company, fostered by Baheal Pharma Group's investment, has earned its place through its sophisticated approach to nuclear medicine diagnostics and treatment, garnering international acclaim for its research efforts.

On November 26, a landmark partnership was cemented in the healthcare and pharmaceutical landscape, as the signing ceremony for the Baheal Pharmal Brand Commercialization North Logistics Base and the Baheal Pharma Advanced Manufacturing Industrial Base Project took place in the Linkong Economic Zone (Langfang). This pivotal event signifies a major advancement in the collaboration between Baheal Pharma Group and the Linkong Economic Zone (Langfang) to expedite the development of these key projects in Langfang. The initiative promises to elevate the regional life sciences industry and catalyze high-quality growth, injecting dynamic energy into the region's expansion efforts.

On the night of November 19, 2023, Qingdao Qingdao Baheal Medical Inc. ("Baheal Medical", 301015.SZ) announced it has entered into landmark commercialization agreements with Guangdong RADIO Pharma Technology Co., Ltd. ("Radio") and Beijing Medis Medical Technology Co., Ltd. ("Medis Medical"). With these agreements, Baheal Medical will exclusively commercialize a portfolio of radio-pharmaceuticals in mainland China, which include Radio's innovative class 1 nuclear medical oncology diagnostic drug, 99mTc-3PRGD2, along with a range of imaging products such as SPECT. In addition, Baheal Medical will also exclusively manage the commercial operations of Medis Medical’s Electromagnetic Localization Puncture Guidance Device and associated products for ultrasound applications.

"The year 2023 marks a decade since the proposal of the Belt and Road Initiative. Throughout this period, Baheal Pharma Group has effectively utilized its prominence within the medical health sector to actively engage with and contribute towards it. Capitalizing on its industry resources, Baheal has been instrumental in revving up growth across participating countries and regions through the provision of high-quality medical health services. As the 10th anniversary of the initiative draws near, Baheal remains deeply committed, taking part in crucial events and making significant contributions to the construction of the Belt and Road with tangible actions.

"On September 28, 2023, Qingdao Baheal Pharmaceutical Co., Ltd., a subsidiary of Shanghai Baheal Medical Co., Ltd., officially held a groundbreaking ceremony for the third phase of its production workshop and supporting construction projects. The event was attended by representative leaders from Jimo District Government of Qingdao city, provincial drug administration, Chairman Fu Gang of Baheal Pharma Group, General Manager Zhuo Yueqiang of Shanghai Xinchangning Group, directors of Baheal Pharma Group, and Zhu Xiaowei, Chairman of BAHEAL Pharmaceutical Co., Ltd. among other distinguished guests, as well as contractors and employees of Qingdao Baheal BAHEAL Pharmaceutical Co., LTD.